Roche’s Vabysmo Grabs Top Growth Spot As Sales Decline
Retreats From MAGE-A4 Bispecifics
The Swiss major’s Q1 earnings show significant growth for Vabysmo, which poses a threat to competitor anti-VEGF drugs from the likes of Novartis and Bayer, even as overall group sales decreased.
